In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...
Generic Viagra (sildenafil citrate) works the same way as Viagra but comes at a lower cost. While Pfizer still manufactures the “little blue pill,” other companies, globally and in the United ...
Pfizer was founded in 1849 by two recent German ... But despite the cultural ubiquity, Viagra has recently faced the inevitable threat from competition and generics, dropping from 92% of the ...
Pfizer employs over 5,000 people in Ireland in manufacturing, sales, administration, logistics and research & development. It ...
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...
Pfizer (NYSE:PFE) has decided not to further develop sisunatovir, an antiviral targeted at respiratory syncytial virus (RSV), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback